Patients successfully treated for hepatitis are less likely to need liver transplants and less likely to die while on a transplant waiting list, according to studies presented at the recent AASLD Liver Meeting. A related analysis looked at the optimal timing of treatment for people awaiting transplants in order to avoid "MELD purgatory."
People with hepatitis C who achieve sustained virological response to treatment had lower liver-related morbidity and mortality rates compared to patients who were not successfully treated, according to research presented at the recent AASLD Liver Meeting.
Complications of advanced liver disease including cirrhosis and hepatic decompensation have risen over the past decade among people with chronic hepatitis C, according to study findings presented at the AASLD Liver Meeting in November. However, in recent years the increase has slowed, especially among those at highest risk -- black patients and people age 60 and over.
Gilead Sciences and AbbVie both announced this month that they have applied for U.S. Food and Drug Administration approval of new all-oral ribavirin-free combination regimens to treat all genotypes of hepatitis C virus (HCV). Gilead's sofosbuvir/velpatasvir/ voxilaprevir and AbbVie's glecaprevir/pibrentasvir have demonstrated high cure rates in Phase 3 clinical trials.